SCHEMBL661287

SCHEMBL661287

CCC(=O)c1cc(OC(C)C)c(OC)cc1I

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 0.54
HTT P42858 1/20 0.39
PDE4B Q07343 1/20 0.39
MAPK1 P28482 2/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ACHE P22303 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP3A4 P08684 2/20 0.36
HTR1A P08908 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
HTR2B P41595 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL661435 0.84 HTT (0.51) HMGCRHTTPDE4BMAPK1ALDH1A1
SCHEMBL10101893 0.84 HMGCR (0.41) HMGCRHTTPDE4BMAPK1ALDH1A1
SCHEMBL661050 0.78 HMGCR (0.60) HMGCRHTTMAPK1ALDH1A1MAPT
SCHEMBL17746918 0.77 HMGCR (0.78) HMGCRHTTMAPTLCKFYN
SCHEMBL15677777 0.76 HMGCR (0.47) HMGCRHTTPDE4BALDH1A1MAPT
SCHEMBL4764754 0.73 HMGCR (0.72) HMGCRHTTALDH1A1MAPTLCK
SCHEMBL661243 0.73 MGAM (0.42) KMT2AACHEL3MBTL1CYP3A4HTR1A
SCHEMBL25139577 0.73 MEN1 (0.62) PDE4BMAPK1ALDH1A1MAPTKMT2A
SCHEMBL661011 0.73 PDE4B (0.62) PDE4BMAPK1ALDH1A1MAPTKMT2A
SCHEMBL660608 0.72 LCK (0.59) HTTALDH1A1MAPTLCKFYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-8536157-B2 Non-steroidal compounds THE UNIVERSITY OF MELBOURNE (AU) 2013-09-17 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed
US-20120046255-A1 NON-STEROIDAL COMPOUNDS THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) 2012-02-23 US disclosed
WO-2008124878-A1 NON-STEROIDAL COMPOUNDS CRYPTOPHARMA PTY LTD (AU) 2008-10-23 WO disclosed
WO-2008124878-A1 NON-STEROIDAL COMPOUNDS CRYPTOPHARMA PTY LTD (AU) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046255-A1 NON-STEROIDAL COMPOUNDS PTGES2, PTGES, PTGES3 HMGCR 74/4885HTT 3412/4885PDE4B 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.